SCHEMBL25966452

SCHEMBL25966452

CSC(=S)O[C@@H]1[C@@H]2O[Si](C(C)C)(C(C)C)O[Si](C(C)C)(C(C)C)OC[C@H]2O[C@H]1n1cnc2c(NC(=O)c3ccccc3)ncnc21

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ PRMT6 Q96LA8 1/20 0.42
▸ PDE4A P27815 2/20 0.41
▸ PDE4D Q08499 2/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ HTR1A P08908 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ ADRB3 P13945 1/20 0.41
▸ PTGS2 P35354 1/20 0.41
▸ PDE3A Q14432 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.41
▸ RXFP1 Q9HBX9 1/20 0.41
▸ P2RY12 Q9H244 6/20 0.38
▸ P2RY2 P41231 1/20 0.36
▸ P2RY1 P47900 1/20 0.36
▸ P2RY6 Q15077 1/20 0.36
▸ PDE4B Q07343 1/20 0.36
▸ PDE4C Q08493 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19500434 0.89 PRMT6 (0.42) PRMT6PDE4APDE4DCYP1A2HTR1A
SCHEMBL19509704 0.89 PRMT6 (0.42) PRMT6PDE4APDE4DCYP1A2HTR1A
SCHEMBL29772230 0.89 PRMT6 (0.42) PRMT6PDE4APDE4DCYP1A2HTR1A
SCHEMBL10457977 0.89 PRMT6 (0.40) PRMT6PDE4APDE4DCYP1A2HTR1A
SCHEMBL10457978 0.89 PRMT6 (0.42) PRMT6PDE4APDE4DCYP1A2HTR1A
SCHEMBL22984002 0.88 PRMT6 (0.40) PRMT6PDE4APDE4DCYP1A2HTR1A
SCHEMBL29674494 0.88 PRMT6 (0.40) PRMT6PDE4APDE4DCYP1A2HTR1A
SCHEMBL10459187 0.86 PDE4A (0.47) PDE4APDE4DP2RY12PDE4BPDE4C
SCHEMBL19509816 0.86 PDE4A (0.47) PDE4APDE4DP2RY12PDE4BPDE4C
SCHEMBL19509705 0.86 PDE4A (0.47) PDE4APDE4DP2RY12PDE4BPDE4C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230203078-A1 SYNTHESIS OF 3'N NUCLEOSIDES THROUGH OXIME INTERMEDIATES AND RELATED COMPOUNDS Janssen Biopharma, Inc. 2023-06-29 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230203078-A1 SYNTHESIS OF 3'N NUCLEOSIDES THROUGH OXIME INTERMEDIATES AND RELATED COMPOUNDS NT5C3B, PNP, NME1 PRMT6 289/4885PDE4A 1011/4885PDE4D 1103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback